The global therapeutic peptide pipeline has expanded considerably since 2020, driven by improvements in manufacturing scale-up, oral bioavailability formulation technologies, and an expanding understanding of incretin biology, tissue repair signaling, and neuropeptide pharmacology. Understanding how peptide candidates advance through clinical phases — and what endpoint and regulatory decisions shape that pathway — is essential context for researchers interpreting trial data and designing preclinical studies intended to support eventual IND filings.
Phase 1 Design: First-in-Human Dosing, PK/PD, and Safety Endpoints
Phase 1 studies for novel peptides typically enroll 20–100 healthy volunteers or (for oncology or rare disease indications) patients refractory to standard therapy. Primary endpoints are pharmacokinetic parameters: maximum observed plasma concentration (Cmax), time to Cmax (Tmax), area under the curve (AUC0–∞), terminal half-life (t½), and volume of distribution. For subcutaneous peptide delivery — the most common route for GH-axis and metabolic peptides — bioavailability relative to IV reference is a mandatory characterization. Safety endpoints follow ICH E6 GCP guidelines: adverse events graded by CTCAE v5.0, serial ECG (QTc monitoring for peptides affecting cardiac ion channels), and immunogenicity assessment by anti-drug antibody (ADA) ELISA at pre-dose and multiple post-dose timepoints. Dose escalation follows modified 3+3 or accelerated titration designs, with cohort review by independent safety monitoring committees.
Phase 2 Design: Proof-of-Concept, Dose-Range Finding, and Biomarker Endpoints
Phase 2 trials establish proof-of-concept in the target indication and identify the optimal dose range for Phase 3. For metabolic peptides (GLP-1R/GIP-R agonists, Retatrutide), primary efficacy endpoints are typically: percent change from baseline in body weight at 20–24 weeks, HbA1c reduction, and fasting plasma glucose. Biomarker-enriched designs — pre-specified subgroup analyses by GIP receptor polymorphism status, for example — allow mechanistic hypothesis testing within the efficacy trial. For tissue repair peptides (BPC-157, TB-500), biomarker endpoints present more complexity: validated surrogate markers for tendon repair (MRI tendon signal-to-noise ratio, histopathological scoring) or GI healing (endoscopic mucosal healing index) must be pre-specified and tied to clinical outcome correlations established in prior research. EMA Guideline on Clinical Investigation of Medicinal Products in the Treatment of Diabetes (CPMP/EWP/1080/00) provides the reference standard for endpoint selection in metabolic indications.
Phase 3 Design: Confirmatory Endpoints, Non-Inferiority Margins, and Regulatory Strategy
Phase 3 confirmatory trials are designed to meet the specific endpoint requirements negotiated with FDA (under SPA agreement, 21 CFR 312.82) or EMA (through Scientific Advice/Protocol Assistance). For peptide-based weight management drugs, FDA requires: primary endpoint of ≥5% mean weight loss in the active arm with statistical superiority to placebo, and co-primary cardiovascular safety endpoint demonstrating MACE non-inferiority (HR upper bound <1.8 in interim, <1.3 for label). For peptide antibiotics or antimicrobials, endpoint guidance follows the 2015 FDA ABSSSI/CABP guidances. Non-inferiority margin selection requires prior data establishing the placebo effect size and acceptable clinical margin — typically derived from meta-analysis of historical trials in the same indication.
Active Peptide Pipeline: Selected Compounds in Formal Development (2025–2026)
Key compounds with active clinical programs: Retatrutide (LY3437943) — GLP-1R/GIP-R/GCG-R triple agonist, Phase 2 published (Jastreboff et al., NEJM, 2023; 24.2% mean weight loss at 48 weeks, 8 mg dose). Phase 3 TRIUMPH program ongoing. CagriSema (cagrilintide + semaglutide fixed-ratio combination) — Phase 3 REDEFINE program for obesity. Pralsetinib — not a peptide but relevant for comparing peptide vs. small molecule regulatory pathway differences. For tissue repair, no GLP-1-class peptide has cleared Phase 3 in musculoskeletal indications as of 2026; most data remains at Phase 2 or preclinical.
Regulatory Pathway Milestones and Research Classification
IND (Investigational New Drug) filing under 21 CFR 312 is required before human administration begins. IND exemptions exist for Phase 1 studies meeting specific criteria, but are not applicable to most novel peptide candidates. EMA Voluntary Harmonization Procedure (VHP) enables multi-country Phase 2 trial approvals in Europe. These compounds in their current research-grade formulations are for research and laboratory use only. Not for unsupervised human consumption.